T
Travere Therapeutics
Developing and delivering therapies for rare kidney and metabolic diseases
About Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies for people living with rare diseases. The company was founded in 2011 and is based in San Diego, California.
Travere Therapeutics has a portfolio of commercial-stage therapies and a pipeline of product candidates for a range of rare diseases, with a focus on rare kidney and metabolic disorders. The company's commercial products include Thiola and Thiola EC for cystinuria, and Chenodal for gallstones. Its pipeline includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy.
The company's business model is focused on the development and commercialization of therapies for rare diseases. Travere Therapeutics generates revenue from the sale of its commercial products. The company also has a patient support program that provides resources and assistance to patients and their families.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- San Diego, United States
- Listing
- IPO 2012
- Employees
- 520
- Open positions
- 55
- Dealroom signal
- 90.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Kidney, Sustainable Development Goals, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, Rare Diseases, Verified Thoroughbreds
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Oct 2020
- Capital deployed
- $2.5M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | May 2026 | $475M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2026 | $0 | — | Palisades Investment Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Travere Therapeutics is 24K monthly website visits, down 31.4% over the last three months. Travere Therapeutics's team grew 27.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Orphan TechnologiesLondon, United Kingdom
$90Mvaluation
PerlaraSan Francisco, United StatesPerlara, PBC is precision drug discovery that leaves no mutation behind
$17Mvaluation
MP
Manchester PharmaceuticalsFort Collins, United StatesManchester Pharmaceuticals has been acquired by Retrophin
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- MCMSMB Capital
Series B and later2 investors entered at this stage
Athyrium Capital Management
Palisades Investment Partners
Other known investors1 additional known investor
International Biotechnology Trust
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Travere Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Travere Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.